Search results
Results from the WOW.Com Content Network
In determining bioequivalence between two products such as a commercially available Branded product and a potential to-be-marketed Generic product, pharmacokinetic studies are conducted whereby each of the preparations are administered in a cross-over study (sometimes parallel study, when a cross-over study is not feasible) to volunteer subjects, generally healthy individuals but occasionally ...
The C max is often measured in an effort to show bioequivalence (BE) between a generic and innovator drug product. [4] According to the FDA, drug quality bioavailability (BA) and BE rely on pharmacokinetic measurements such as AUC and C max that are reflective of systemic exposure.
The publication does not include drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal Tablets and Librax Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]).
"Metrics to characterize concentration-time profiles in single- and multiple-dose bioequivalence studies". Bioequivalence Studies in Drug Development: Methods and Applications. Statistics in Practice. Chichester, UK: John Wiley and Sons. pp. 17– 36. ISBN 978-0-470-09475-4; Chow, Shein-Chung; Liu, Jen-pei (15 October 2008). Design and Analysis ...
A drug is considered highly soluble when the highest dose strength is soluble in 250 ml or less of aqueous media over the pH range of 1 to 6.8. The volume estimate of 250 ml is derived from typical bioequivalence study protocols that prescribe administration of a drug product to fasting human volunteers with a glass of water.
Many scientific endeavors are dependent upon accurate quantification of drugs and endogenous substances in biological samples; the focus of bioanalysis in the pharmaceutical industry is to provide a quantitative measure of the active drug and/or its metabolite(s) for the purpose of pharmacokinetics, toxicokinetics, bioequivalence and exposure ...
Bioequivalence studies have shown that benzhydrocodone/APAP is bioequivalent to other immediate-release hydrocodone combination products such as 7.5 mg hydrocodone/200 mg ibuprofen (Vicoprofen) and 7.5 mg hydrocodone/325 mg acetaminophen (Norco). [4] Benzhydrocodone is metabolized to hydrocodone by intestinal enzymes.
Head-to-head settings with OFM have proven particularly useful for the evaluation of topical generic products, which need to demonstrate bioequivalence [9] to the reference listed drug product to obtain market approval. Applications of dOFM include ex vivo studies with tissue explants and preclinical and clinical in vivo studies.